強
強気
強気 · 25%TAK
$18.07
シナリオ価格
$19.670
+0.222 (+1.13%)終値時点
Loading chart…
- 高値
- 19.705
- 始値
- 19.670
- 出来高加重平均価格
- 19.65
- 出来高
- 2.83M
- 時価総額
- 40.51B
- 安値
- 19.561
- 売買代金
- 55.55M
- EV/EBITDA（TTM）
- 3.05
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies.
AI分析 of Takeda Pharmaceutical Co Ltd (TAK)
買いTakeda Pharmaceutical Co Ltd (TAK) appears to be a good buy right now due to its current price of 18.73, which is above the 200-day simple moving average of 17.25, suggesting a bullish trend. Additionally, the stock has shown a strong year-to-date change of +19.91% and a one-year change of +36.52%, indicating solid performance. The RSI of 67.41 suggests that the stock is nearing overbought conditions but still has room for growth. The main risk is the negative net income reported in Q4 2026, which was -368.47 billion JPY, highlighting potential volatility in earnings.
バリュエーション指標
Takeda Pharmaceutical Co Ltd（TAK）の現在の予想PERは11.47で、5年平均は25.23です。
Alphio AI による TAK の価格シナリオ
シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト（25 / 50 / 25）であり、保証ではありません。
イベントタイムライン
ニュース
5.010-15NewsfilterORZEYFUL Approved for Launch in Japan and China
- 9.009-30Newsfilter
Zasocitinib Shows Superiority in Psoriasis Treatment
- 9.009-22Newsfilter
Takeda Unveils New Data at ESMO Congress on Cancer Treatments
- 8.509-18Newsfilter
Takeda Awards $22.2 Million to 2026 Global CSR Partners
- 8.509-14Newsfilter
Takeda's Zasocitinib Receives FDA Priority Review for Psoriasis
TAK のよくある質問 — Alphio AI が回答
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies. It operates in the Healthcare sector.
Takeda Pharmaceutical Co Ltd (TAK) appears to be a good buy right now due to its current price of 18.73, which is above the 200-day simple moving average of 17.25, suggesting a bullish trend. Additionally, the stock has shown a strong year-to-date change of +19.91% and a one-year change of +36.52%, indicating solid performance. The RSI of 67.41 suggests that the stock is nearing overbought conditions but still has room for growth. The main risk is the negative net income reported in Q4 2026, which was -368.47 billion JPY, highlighting potential volatility in earnings.
コミュニティ
もっと見る ↗投稿はまだありません
登録またはログインして議論に参加本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。